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Abstract
Although leishmaniases are endemic in 98 countries, they are still considered neglected tropical diseases. Leishmaniases
are characterized by the emergence of new virulent and asymptomatic strains of Leishmania spp. and, as a consequence,
by a very diverse clinical spectrum. To fight more efficiently these parasites, the mechanisms of host defense and of
parasite virulence need to be thoroughly investigated. To this aim, animal models are widely used. However, the results
obtained with these models are influenced by several experimental parameters, such as the mouse genetic background,
parasite genotype, inoculation route/infection site, parasite dose and phlebotome saliva. In this review, we propose an
update on their influence in the two main clinical forms of the disease: cutaneous and visceral leishmaniases.
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Background
Leishmaniases are caused by pathogens of the genus
Leishmania and are characterized by an important clin-
ical and epidemiological diversity. According to the
World Health Organization (WHO), leishmaniases occur
in four continents and are endemic in 98 countries [1]. The
causative parasites are classified according to genetic,
biological and immunological criteria. More than 30
Leishmania spp. are known of which 20 are pathogenic
for humans (for a taxonomic table, see [2]). In humans,
this disease can have several clinical manifestations of vari-
able severity: mucosal leishmaniasis (a mutilating disease),
diffuse cutaneous leishmaniasis (a long-lasting disease due
to a deficient cell-mediated immune response), cutaneous
leishmaniasis (disabling with multiple lesions) or visceral
leishmaniasis, which is fatal if untreated (see for reviews [3,
4]). Leishmaniasis can also be asymptomatic in humans [5,
6] and in animal reservoirs [7, 8]. It is worth noting that a
single species of Leishmania may cause several disease
forms [3].
Drug-resistant Leishmania isolates or emerging virulent
strains are often described [9, 10]. It is crucial to under-
stand how these new strains disseminate and are controlled
by the host immune system to fight against them. To
investigate the pathogenic diversity, the impact of the host
genetic background and of the Leishmania genotypes,
animal models are widely used. Classically, in infected
animals, parasite-activated CD4+ T cells rapidly proliferate
in the lymph nodes, differentiate and secrete specific cyto-
kines. Th1 cells secrete IL2, IFNγ and TNFα, leading to
macrophage activation and parasite elimination. On the
other hand, the Th2 response is associated with IL4, IL5
and IL13 production and with parasite proliferation (for
review see [11]). When studying a newly isolated strain, the
experimental settings have to be carefully designed and
several parameters must be taken into account. The object-
ive of this review is to summarize results on the pathogenic
mechanisms in mice infected by Leishmania spp. We will
focus on the two main clinical forms: visceral leish-
maniasis (VL) and cutaneous leishmaniasis (CL). We
will first describe the experimental data on the influence of
the genetic background in mouse models of VL and CL
caused by Leishmania donovani and L. infantum and of CL
caused by L. major, L. mexicana and L. tropica. Then, data
obtained in mouse models of VL by L. infantum and of CL
by L. major will be reviewed, particularly: (i) the immune
cells involved and the associated-immune response
and (ii) the parameters (mouse and parasite genotypes,
parasite dose and inoculation route) that influence the
infection outcome.* Correspondence: mallorie.hide@ird.fr
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Human VL is the most severe form of this disease and
occurs when infected people are left untreated. Ninety
percent of reported cases of VL are found in Bangladesh,
Brazil, India, Nepal and Sudan (WHO). Approximately,
0.2 to 0.4 million cases of VL are reported each year and
VL causes 20,000 to 40,000 deaths annually [1]. It is caused
by parasites of the Leishmania donovani complex: L.
donovani, L. archibaldi and L. infantum (syn. L. chagasi).
The main causative agents of VL in humans are L. dono-
vani and L. infantum, whereas L. infantum can cause CL
(see below) and is the main VL-causing parasite in dogs,
which are considered to be Leishmania spp. reservoirs [3].
Hereafter, we will describe the main experimental parame-
ters that need to be taken into account when studying vis-
ceralizing Leishmania strains.
Mouse genetic background
Susceptibility and resistance to Leishmania infection in
humans and in mice are regulated by genetic determinants
[12]. In the mouse, two main loci have been described:
Lsh and H2 (the major histocompatibility complex). The
Lsh locus on mouse chromosome 1, with Nramp1
(Slc11a1) as the main candidate gene [13], influences the
natural resistance to L. donovani infection (control of
parasite load in liver and spleen) [14]. In mice harboring
wild type Scl11a1, such as the CBA mouse strain, parasite
proliferation in liver is hindered. Conversely, in mice with
mutant Scl11a1, such as the BALB/c and C57BL/6 strains,
parasite growth is unrestrained [15]. The H2 locus [16] is
involved in the development of the adaptive immunity
and overcomes the innate susceptibility to L. donovani
caused by Scl11a1 mutations [15]. Like for L. donovani, L.
infantum primary infection is also initially controlled by
the Lsh locus and then by the H2 locus. Both loci are
involved in the development of the acquired immune
response [17]. For instance, L. infantum susceptible mice
(with mutant Scl11a1) harboring the H2-b or H2-r alleles,
show a “cure” phenotype associated with a strong reduc-
tion of the parasitic load in liver. Conversely, H2-d, H2-q
and H2-f susceptible mice are characterized by a “non-
cure” phenotype. Mice can thus be classified in four
phenotypic categories: resistant, susceptible and when
susceptible, in cure and non-cure (Table 1). Non-cure mice,
such as the BALB/c strain, will spontaneously progress to a
chronic phase of the disease without total parasite clearing.
Conversely, in cure mice, such as the NMR1 strain, the
parasite load is very low and parasites can be fully elimi-
nated in some cases.
In conclusion, it is clear that the mouse genetic back-
ground influences the Leishmania infection outcome
and this feature must be taken into account when
designing experiments. Although BALB/c mice will not
die of VL (differently from untreated humans), they can
be used to study the immunopathology changes occur-
ring during VL. Indeed, they present clinical features of
human VL, such as hepatosplenomegaly or disruption of
splenic tissue. However, the infection outcome depends
also on the ability of the infected mice to induce a good
Th1 immune response as well as on the inoculation
route and injected dose, as discussed hereafter.
Immune control of infection
From an immunological point of view, the main feature
of VL is its organ specificity. Indeed, studies on VL pro-
gression in mice highlighted that the major responding
tissues (spleen and liver) present distinct patterns in
term of immune response and parasite control. When
injected intravenously in BALB/c mice, more than 95 %
of L. infantum promastigotes are rapidly cleared from
the circulation by highly phagocytic macrophages of the
spleen marginal zone [18]. After pathogen uptake, mac-
rophages exert their leishmanicidal activity through ni-
tric oxide (NO) synthesis. During the course of
infection, the parasite burden is progressively controlled
[19] with a peak of parasitemia at week 8 of infection
[20]. In the spleen, the course of parasite burden reflects
the cytokine production kinetics and the activation of
the different classes of immune cells. At the beginning
of infection (first 4 weeks), parasite replication is associ-
ated with the immune cell inability to produce IFNγ and
IL2 (macrophage-activating cytokines), whereas produc-
tion of IL4 or IL5 is conserved [21, 22]. Conversely, IL10
and TGFβ (macrophage-inhibitory cytokines) are pro-
duced by cells of the spleen marginal zone and of the
red pulp, respectively. IL10 and TGFβ are thought to
contribute to the establishment of infection and parasite
replication [19]. After the first 4 weeks of infection,
CD4+ T, CD8+ T and natural killer (NK) cells recover
their capacity to produce IFNγ, thus promoting the
macrophage microbicidal activity with NO synthesis
Table 1 Influence of the mouse genetic background on visceral leishmaniasis outcome
Locus Phenotype Mouse strain Reference
Lsh resistant NMR1, A2G, HR, Ash, CD2, CBA [14, 15, 17]
Lsh susceptible B10D2, C3H, PO, BALB/c, C57BL/6 [14, 15, 17]
Lshs/H2k/b; H2r cure B10.A4R [17]
Lshs/H2d; H2q; H2f non-cure B10.HTG, B10.D2/n [12, 17]
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and control of granuloma formation in liver (see next
paragraph) and ultimately parasite burden reduction
[21]. In synergy with IFNγ, IL17A also contributes to
macrophage activation with NO production, leading to
parasite clearance [23]. Nevertheless, infection in the
spleen is maintained during the entire VL course. This
parasite persistence may be due to sustained TGFβ pro-
duction by CD4+ CD25+ T cells (Treg) that contributes
to immunosuppression [24].
In liver, the infection time course is different. After
injection in the lateral tail vein, promastigotes invade the
resident macrophages, Kupffer cells and dendritic cells
where they become amastigotes and replicate. During
acute infection (first 2 weeks), parasite growth is uncon-
trolled, due to elevated TGFβ levels and ineffective Th1
response [25]. This correlates with the peak of parasite
burden observed between 2 and 8 weeks post-infection.
Liver infection is then resolved through the formation of
granulomas that are characterized by parasitized Kupffer
cells surrounded by a mantle of lymphocytes [26].
Finally, after 8 weeks of infection, amastigotes are almost
absent in granulomas and infection is resolved [26].
In VL, the organ-specific immunity with elimination
of parasites in liver and their persistence in the spleen
directly reflects the observed immune response. This
chronic status is critical because the host becomes more
susceptible to secondary infections. Thus, to develop
and evaluate new vaccines or therapies against leishman-
iases, it is crucial to determine the role of each immune
cell type in the establishment of the cellular immune
interplay resulting in the control of the infection.
For VL, a thorough understanding of the mechanisms
underlying the protective immune response in liver and
the failure in spleen would allow the development of
new candidate vaccines and of new strategies or treat-
ments to eliminate the parasite in infected people.
Tissue of origin and parasite genotype
Another question is whether the disease pattern differs
depending on the tissue of origin of the parasites used to
infect mice (isolated from cutaneous or visceral forms in
humans). Comparison of the infection profiles (parasite
burden in spleen and liver) in BALB/c mice of 22 L.
infantum strains isolated from patients with CL or VL
revealed a great variability of infection profiles (progres-
sive, controlled or undetectable infection) [27]. The para-
site zymodeme and the host immune status did not have
any influence on the infection profile. However, no strain
of cutaneous origin caused a visceralizing form in mice
[27]. In susceptible mice, histopathological analysis of the
liver revealed no difference whatever the L. infantum
strain used, although a more pronounced liver granuloma-
tous response was observed with visceralizing strains [28].
Interestingly, the visceralizing and infection profiles were
preserved in BALB/c and C57BL/6 mice, both susceptible
to infection with a non-cure and a cure profile respect-
ively, suggesting a clear role of parasite factors on the in-
fection outcome. This was confirmed by the finding that
the infection kinetics were similar following experimental
infection of immunodeficient C.B-17 SCID and congenic
BALB/c mice, although the parasite load was higher in
immunodeficient animals [29].
Moreover, L. infantum strains belonging to the same
zymodeme (MON-1) can lead to different infection pro-
files in mice. The most pathogenic strains induced sple-
nomegalia and higher parasite load in spleen and liver
associated with higher IgG1, TGFβ and reduced IFNγ
production [30]. This effect was not related to the host
species (dog or human) from which the parasites were
isolated [30]. These observations highlight the intra-
strain specific virulence variability and confirm that in
VL, parasite virulence is a clonal or inbred dominant
trait within each strain (infection study of 11 clones de-
rived from three strains of known virulence) [31].
The influence of the host immune status on the strain
virulence is not well known. Indeed, strains isolated
from immunosuppressed patients display either high
[27] or low virulence [30].
In conclusion, it is difficult to extend experimental re-
sults in mouse models obtained with a given Leishmania
strain to other strains even if they are genetically related
or responsible for the same clinical form. Therefore, it is
crucial to analyze all new parasite isolates and the corre-
sponding immune response in mice. Such studies are
particularly recommended for parasite stocks that cause
large epidemics or non-pathogenic and silent leishman-
iasis forms in humans. Prospective studies in endemic
areas also are important to better understand the basis
of the protective immune response in humans and to
develop specific and more efficient treatments.
Inoculation route and parasite dose
Several inoculation routes have been tested (Table 2). It
appears that the parasite load (reflecting the immune re-
sponse strength) depends not only on the parasite dose
that is inoculated, but also on the chosen injection route.
For the LIVT-1 strain, the subcutaneous route seems to
be less efficient (based on the parasite load in the spleen)
than the intravenous one, when mice are inoculated with
medium doses of parasites (105); however, it has been not
demonstrated for higher doses (106 and 107) [32]. More-
over, the parasite load in the liver is higher following intra-
venous inoculation compared to the subcutaneous route
and the response is dose-dependent [32].
A clear dose effect on parasite load was observed in
BALB/c mice inoculated subcutaneously with L. infantum
[33]. Mice inoculated with low doses (103) showed a min-
imal infection associated with a Th1 response (IFNγ and
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NO production in spleen), whereas high doses (107) led to
high parasite burden in spleen and lymph nodes as well as
to a Th2 response [33].
By assessing several inoculation routes, Kaur et al.
showed that the subcutaneous route is less efficient than
the intradermal, intraperitoneal and intracardiac routes
in term of liver parasite load [34]. Again, a clear dose
effect on parasitemia was detected. High doses inocu-
lated by intracardiac injection led to the highest liver
parasite load and were associated with a Th2 immune
response [34]. However, the Th1 immune response ne-
cessary for the establishment of resistance in BALB/c
mice was strongest when mice were inoculated with low
doses of parasites via the subcutaneous or intradermal
routes. This was associated with maximum IFNγ pro-
duction and high level of IgG2a [33, 34]. It is worth
noting some discrepancies in studies assessing the same
dose and the same route. For example, differently from
Rosypal et al., Oliviera and colleagues demonstrated that,
at high dose (107), parasite load is higher when mice are
inoculated subcutaneously rather than intravenously.
Overall, it is difficult to compare different studies because
of the different parasite strains and parasite load determin-
ation methods. This stresses again that results obtained
with a given stock cannot be fully transposed to another
one. Moreover, although all the studies summarized here
Table 2 Inoculation route and parasite dose influences on visceral leishmaniasis outcome in susceptible BALB/c mice
Infection route Parasite dose Parasite strain Liver load Spleen load Th1 response Th2 response Reference
Subcutaneous 105 LIVT-1 + - ND ND [32]
106 + + ND ND
107 + + ND ND
103 MHOM/BR/1970/BH46 +/- ++ + + [33]
105 + +++ + +
107 ++ ++++ + +++
103 MHOM/IN/80/DD8 +/- ND +++ + [34]
105 + ND ++ +
107 + ND ++ ++
Intradermal 103 MHOM/IN/80/DD8 + ND +++ + [34]
105 ++ ND ++ +
107 ++ ND ++ +
107 MHOM/ES/92/LLM-320 +++ +++ + + [38]
Intraperitoneal 103 MHOM/IN/80/DD8 ++ ND ++ ++ [34]
105 +++ ND + ++
107 +++ ND + +++
107 MCAN/PT/94/IMT205 ND + ND ND [37]
Intracardiac 103 MHOM/IN/80/DD8 ++ ND ++ ++ [34]
105 +++ ND + ++
107 ++++ ND - +++
107 MHOM/IN/1993/B12302 +++ ++ ++ ++ [35]
Intravenous 105 LIVT-1 + + ND ND [32]
106 ++ + ND ND
107 +++ + ND ND
107 MHOM/BR/1970/BH46 + + + ++ [33]
103 MCAN/ES/96/BCN150 + + +/- - [36]
105 ++ ++ +/- +/-
106 ++ +++ + ++
104 MHOM/ES/92/LLM-320 +/- + ND ND [38]
105 + ++ ND ND
106 ++ +++ ND ND
107 MCAN/PT/94/IMT205 ND + ND ND [37]
ND not done
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were performed using BALB/c mice, we cannot assume
that the animals were genetically identical and this could
account for the different responses sometimes observed
after Leishmania infection.
The intracardiac route is responsible for the develop-
ment of Th2 immune response that is characterized by
IL4 production and increased levels of IgG1 and is asso-
ciated with IL10 production by Treg cells, thus allowing
the establishment of a persistent infection [24, 34].
Although another study described a quite different im-
mune response after intracardiac infection [mixed acti-
vating (IFNγ and TNFα)/deactivating (TGFβ) cytokine
response] [35], this route seems to be effective in term
of infection persistence. Indeed, intracardiac inocula-
tion leads to progressive VL with parasite persistence in
the spleen 4 months after the infection and accompan-
ied by massive splenomegaly [35].
Intravenous inoculation seems to lead to effective in-
fection (based on parasite load) whatever the dose used,
with parasite persistence in spleen and liver when high
doses are injected [36]. Liver lesions are prominent in
intravenously inoculated mice, whereas they are almost
inexistent in mice injected subcutaneously. However,
heterogeneity is observed among animals as already
described for spleen parasite load [37]. Liver granuloma
formation seems to depend on the dose used: high
numbers of mature and sterile granulomas are observed
when mice are inoculated with low doses, whereas no
parasite clearance is detected after injection of high
doses [36]. However, it is worth noting that only mice
inoculated with low doses could mount a protective
response in the liver and bone marrow, associated with
parasite clearance.
Intradermal inoculation of high parasite doses (107)
leads to chronic infection with parasite persistence in
spleen and lymph nodes, Th1/Th2 cytokines production
(IFNγ, IL4) and partial clearance in the liver [38]. When
inoculated with low (103) or medium (105) doses, mice
are effectively infected, but present a lower parasite
load and a Th1-dominant immune response [33].
In conclusion, although the subcutaneous or intra-
dermal routes mimic the natural infection routes, they
require high doses of parasites to cause a good and
persistent infection. Lower doses can be recommended
for vaccination protocols because the generated im-
mune response seems to be sufficient for long-term
protection. One study reported that the intraperito-
neal route leads to higher homogeneity of infection in
term of parasite load and thus might be more appro-
priate to study new isolates [37]. Conversely, the intra-
venous route leads to heterogeneous parasite loads
among animals and, consequently, errors in the inter-
pretation of the results could occur when analyses are
performed on pooled animals.
Influence of phlebotome saliva
Leishmania parasites are classically injected in the skin
together with saliva by an infected sandfly during a
blood meal. For VL, studies on phlebotome saliva are
mainly focused on its modulatory effect on the immune
response or as a vaccine candidate rather than on its
influence on the primary infection outcome (for review
see [39]). To our knowledge, only two studies reported
that, differently from CL (see below), salivary extracts
do not to have a significant role in VL establishment in
dogs and mice [38, 40]. Dogs intradermally inoculated
with L. chagasi stationary promastigotes together with
or without Lutzomyia longipalpis salivary gland extract
did not show any infection, suggesting that the pres-
ence of salivary proteins is not sufficient for effective
infection through the intradermal route [40]. In BALB/
c mice, intradermal injection of L. infantum promasti-
gotes with or without sandfly salivary extracts led to
effective visceralization in both cases, showing that sal-
ivary products do not influence the infection course
(parasite burden in spleen, liver and lymph nodes) [38].
Further studies are needed to validate these results and
to determine the potential effect of sandfly salivary
components on L. infantum visceralization capacity and
infection outcome.
In conclusion, when studying VL in mice, it is im-
portant to consider the parasite dose as well as the
route of inoculation because they clearly influence the
development of the T helper response and consequently
the infection outcome. The study of the chronic phase
of infection requires an inoculation route (intravenous
or intradermal) that allows the long-term establishment
of the infection. Conversely, for studying the acute
phase of infection, the inoculated dose needs to be pre-
cisely controlled because a more intense immune re-
sponse is observed with high doses. For vaccination
studies, low doses of parasites (104) can be used be-
cause the elicited immune response can protect on the
long term.
Cutaneous leishmaniasis
The incidence of human cutaneous leishmaniasis (CL)
is of about 0.7 to 1.2 million cases each year [1]
(WHO, 2014). According to the WHO, 90 % of CL
cases occur in Afghanistan, Brazil, Iran, Peru, Saudi
Arabia and Syria. It is usually a self-healing disease,
but in the presence of multiple lesions, CL can lead to
lifelong aesthetic stigma [4]. CL is caused by several
Leishmania species: L. major, L. tropica, L. mexicana,
L. amazonensis, L. braziliensis and L. guyanensis [2, 3].
L. infantum, a classically visceralizing species, can also
present an unusual skin tropism, thus rarely causing
limited cutaneous lesions at the biting site [41].
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Mice genetic background
Studies on the infection phenotype in mice with differ-
ent genetic background and in inbred congenic mice
have allowed the identification of several loci involved in
the infection control (Table 3). Analysis of the lesion size
in the progeny from crosses between resistant and sus-
ceptible mice following intradermal infection with L. tro-
pica led to the hypothesis that susceptibility (C57BL/6 x
Balb/c) or resistance (C3H/HeN x P/J) to CL could be
controlled by a unique locus with minor influences by
other genes [42, 43]. However, the finding that not all
animals with cutaneous lesions will develop a systemic
infection suggests that different genes may be involved
in this two forms of disease [42, 43].
High throughput genetic screening revealed a complex
picture. Indeed, some loci that control CL are common
to several Leishmania spp., while others are specific. The
Lsh1 locus on chromosome 1 can control the outcome
of cutaneous infections caused by L. mexicana, but not
by L. major [44, 45]. The H2 locus also influences the in-
fection outcome, but more weakly than the Lsh1 locus.
Depending on the HLA allele, mice have been classified
as resistant (H2-r, -s, -a, -k) or susceptible (H2-b, -d, -q),
with slowing resolving lesions following infection by L.
major, L. tropica or L. mexicana [46–48].
Studies based on genome-wide analysis of resistance
versus susceptibility phenotypes in the offspring of vari-
ous intercrosses allowed the identification of different
loci involved in mouse susceptibility or resistance to CL.
For instance, the scl-1 and -2 (for susceptibility to cuta-
neous leishmaniasis) loci on chromosome 11 [49] are in-
volved in the control of mouse susceptibility. The scl-1
locus controls the healing versus non-healing responses
to L. major and the scl-2 is responsible for the develop-
ment of cutaneous lesions induced by L. mexicana [49].
On the other hand, others loci are involved in mouse re-
sistance as the Lmr-1, -2 and -3 (for Leishmania major
resistance) loci that contribute to control skin lesion
healing (for review see: [50, 51]. Currently, more than 30
loci have been identified as involved in the complex con-
trol of L. major-induced CL. Indeed, a single Quantita-
tive Trait Locus (QTL) does not account for the overall
phenotype variance, but rather is responsible for the
control of a specific infection or pathogenic aspect. For
example, Lmr-5 regulates parasite load in spleen and
Lmr-20 in lymph nodes, whereas Lmr-5 and Lmr-21
control the development of skin lesions [52]. Thus, con-
trary to VL where only two main loci (Lsh1 and H2) are
involved, CL outcome is regulated by the combination
of several loci. The susceptibility/resistance of different
mouse strains to CL is summarized in Table 4. The
highly susceptible BALB/c mice and the resistant
C57BL/6 J mice are widely used to study both the genet-
ics and biology of the host response to CL.
Due to the complex control of CL pathogenesis, we
decided to focus mainly on L. major because it is the
most studied strain. In experimental settings for in vivo
studies, some parameters, described hereafter, need to
be considered.
Immune control of infection
Differently from VL induced by L. donovani complex
species where a mixed Th1/Th2 response is observed
during the infection course, the outcome of L. major
induced-CL depends on the development of polarized
Th1 or Th2 responses associated with resistance or sus-
ceptibility, respectively [53]. Indeed, in resistant mice
(C57BL/6), a Th1-oriented immune response, associated
with IFNγ, IL2 and IL12 production, is clearly observed.
At the infection site, few parasites remain viable thanks
to the presence of CD4+ CD25+ regulatory T cells that
produce IL10 [54]. Conversely, susceptible mice (BALB/
c) develop a Th2 immune response with IL4 production,
leading to the development of uncontrolled lesions and
disseminated visceral infection. Treg cells that produce
IL4 and IL10 cytokines also play a role in disease pro-
motion by expanding, or regulating the Th2 population
[55]. In these mice, lesion severity is also associated with
the production of IL17 that promotes neutrophil immi-
gration and thus lesion progression [56].
In experimental mouse models of CL, several cell types
are found in the lesions: neutrophils [57], macrophages
[58], eosinophils [58], lymphocytes [59], mast cells [60]
and NK cells [61]. These cells play a role during the
different phases of the infection: (i) silent phase (no le-
sion formation or inflammation detection) with parasite
invasion of skin resident macrophages and neutrophils;
(ii) lesion development associated with migration and
Table 3 Influence of the mouse genetic background on cutaneous leishmaniasis outcome
Locus Phenotype Species Reference
Lsh Resistance/susceptible (liver parasite load) L. mexicana [45, 48]
H2r, s, a, k Lesion resorption L. major, L. tropica, L. mexicana [46–48]
H2b, d, q Slow resolution of lesions L. major, L. tropica, L. mexicana [46, 48]
Scl1 Lesion healing L. major [16]
Scl2 Lesion development L. mexicana [16]
Lmr1, 2, 3…. Lesion healing L. major [50–52]
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activation of cells of the innate immune system (mast
cells, neutrophils, monocytes); (iii) lesion involution with
migration of dendritic cells and T cells; and (iv) chronic
phase characterized by lesion resolution and associated
with parasite persistence, mainly in macrophages, and
lifelong immunity [58].
Thus, immunity to L. major depends on multiple cell
types that cooperate for the development of an effective
and protective immune response. Understanding their re-
spective role and how to modulate their function could
lead to new therapeutic approaches for immunization and
long-lasting protection. For example, as dendritic cell acti-
vation is required for protective immunity, vaccines using
infected or antigen-loaded dendritic cells could lead to the
development of a specific and efficient immune pro-
tective response.
The remaining part of this review will focus on the
parameters that influence the mouse immune response
to CL: parasite genotype, parasite dose, site of the intra-
dermal inoculation (ear dermis, dorsal skin and hind
footpad), and associated adjuvant (saliva).
Parasite genotype
Few reports have assessed the natural virulence variability
of different L. major strains in the same mouse model and
the associated immune response. Li et al. compared the in-
fection outcome of two clones derived from the same L.
major strain. They found that the avirulence of the S2
clone, characterized by spontaneous lesion healing, was not
correlated with its capacity to infect macrophages or the in-
oculated dose, but with parasite factors [62]. The study of
the infection outcome in BALB/c mice inoculated with 19
L. major strains (12 from Tunisia, zymodeme 25; and 7
from the Middle East, zymodeme 26, 68, 70 or 103) re-
vealed a large heterogeneity of disease severity (footpad
lesion size) [63]. Interestingly, all Middle East strains
presented high or intermediate virulence, whereas most
Tunisian strains (10/12) showed lower virulence. This was
correlated with their pathogenicity in humans. Higher viru-
lence could be associated with a greater capacity to infect
bone marrow-derived macrophages, faster growth in cul-
ture and the induction of a stronger Th2 response in vivo.
Moreover, the in vitro study of two of these L. major clones
(zymodeme 25) highlighted their different capacity of
human dendritic cell invasion, a feature that could modu-
late the innate immune response [64].
The heterogeneity of lesion size in function of the
parasite genotype was confirmed by another study in
BALB/c mice [65]. In addition, these authors observed
reproducible differences in lymph node parasite burden,
depending on the L. major strain, at week 8 after inocu-
lation. Specifically, the highest pathogenicity (based on
the parasite load) was associated with induction of the
Th2 immune response, whereas strains with intermedi-
ate or low pathogenicity elicited predominantly a Th1
immune response. Recently, the study of four Iranian
strains in BALB/c mice highlighted their high diversity
of lymph node parasite burden and cytokine expression
and confirmed that the strain causing the lowest parasite
burden induced mainly a Th1 response [66].
These results clearly demonstrate the importance of
the parasite genotype in CL development, although one
study suggested that high parasite dose could be the only
important determinant of the Th1/Th2 response, inde-
pendently of the parasite or the mouse genotypes [67].
Parasite dose
Concerning the inoculated dose (Table 5), an initial
study found that in susceptible BALB/c mice, no clinical
sign was visible (such as increase in footpad size) follow-
ing subcutaneous inoculation of low parasite doses (102
to 103 parasites). Conversely, inoculation of high doses
(105 to 107 parasites) led to significant footpad enlarge-
ment [68]. This dose-dependent effect was confirmed in
other studies. For example, lesions were apparent in all
BALB/c mice injected with 104 (MHOM/IR/-/173 strain)
or 106 (MHOM/IL/80/Friedlin strain) parasites [67].
Uzonna et al. confirmed that CL severity (asymptomatic
with no lesion but IgG2a response > IgG1; apparent le-
sions with identical IgG1 and IgG2a levels; large lesions
and even foot loss) in BALB/c mice depends on the
injected dose [69]. Moreover, subclinically infected
BALB/c mice are resistant to a secondary pathogenic in-
fection (106 parasites, footpad injection) and, thus, could
be used in vaccination strategies [69]. However, not all
mice infected with low parasite doses will develop a sub-
clinical form of CL. Indeed, susceptible BALB/c mice in-
oculated with 102 parasites showed significant pathology
(antibody response and parasite detection in lymph
nodes) and then progressed to a chronic phase where le-
sions stop increasing in size and eventually will resolve
[69, 70]. In C57BL/6 mice, whatever the dose (102 to
107), lesions resolved and this was associated with the
induction of a Th1 immune response (tested for the 102
and 106 doses) [70]. However, in another study, the clas-
sical clinical response (lesion healing and Th1 immune
response) was observed only when C57BL/6 mice were
inoculated with high parasite dose (106). Conversely, in
Table 4 Susceptibility of mouse strains to cutaneous
leishmaniasis
Phenotype Mouse strain Reference
Susceptible C57BL/10 (B10), B10.D2/n,
BALB/c, SWR/J, P/J, CcS-16
[46, 48, 52]
Resistant A, AKR, B10.BR, B10.RIII,
B10.D2, CBA, C3H, C57BL/6,
DBA/2 J, STS, 129/Sv, CcS-5
[46–48, 52]
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animals inoculated with low doses (103), an unexpected,
but transient Th2 response occurred first and was then
reversed by the activation of IFNγ − producing CD8+ T
cells [71].
In summary, the inoculated dose can influence the im-
mune response and thus CL severity, which is also
dependent on the mouse genetic background. Specific-
ally, in susceptible mice (i.e. BALB/c strain), high doses
(105 to 107 parasites) lead to persistent infection associ-
ated with a Th2 immune response. Low doses (101 or
102 parasites) induce a Th1 response and thus could be
used in vaccination studies. However, a “serodeconver-
sion” may occur several (9 to 18) months after infection.
With intermediate doses (103-104), a mixed Th1-Th2
immune response is observed.
In resistant mice (i.e., C57BL/6 strain), effective lesion
development is observed only with high doses (106-107).
Inoculation of low doses (100 metacyclic promastigotes)
at a dermal site (for instance, ear dermis) is recom-
mended to mimic the natural transmission and induces
two distinct disease phases [58, 72]. First, a clinically
silent phase occurs during the first 4–6 weeks and is
Table 5 Influence of the parasite dose on cutaneous lesion size and the concomitant immune response
Parasite dose Mouse strain Parasite strain Lesion size (footpad) Th1 response Th2 response Reference
101 BALB/c MHOM/IL/80/Friedlin +/- +++ +/- [69]
BALB/c MHOM/IR/-/173 +/- ND ND [67]
102 BALB/c MHOM/IL/80/Friedlin +/- ND ND [68]
BALB/c MHOM/IL/80/Friedlin - ++ +/- [67]
BALB/c MHOM/IR/-/173 + ++ +/- [67]
BALB/c MHOM/IL/80/Friedlin + + - [69]
BALB/c MHOM/IR/-/173 +/- ++ - [70]
C57BL/6 MHOM/IR/-/173 - [70]
103 BALB/c MHOM/IL/80/Friedlin + - +/- [68]
BALB/c MHOM/IL/80/Friedlin - ND ND [67]
BALB/c MHOM/IL/80/Friedlin ++ + + [69]
BALB/c MHOM/IR/-/173 + ND ND [70]
C57BL/6 MHOM/IL/80/Friedlin + + ++ [71]
C57BL/6 MHOM/IR/-/173 - ND ND [70]
104 BALB/c MHOM/IL/80/Friedlin +/++ ND ND [68]
BALB/c MHOM/IL/80/Friedlin + ND ND [67]
BALB/c MHOM/IR/-/173 ++ ND ND [67]
BALB/c MHOM/IL/80/Friedlin ++ +/- + [69]
BALB/c MHOM/IR/-/173 + ND ND [70]
C57BL/6 MHOM/IR/-/173 +/- ND ND [70]
105 BA[71]LB/c MHOM/IL/80/Friedlin ++ ND ND [68]
BALB/c MHOM/IL/80/Friedlin +++ +/- ++ [69]
BALb/c MHOM/IR/-/173 + ND ND [70]
C57BL/6 MHOM/IR/-/173 +/- ND ND [70]
106 BALB/c MHOM/IL/80/Friedlin +++ - ++ [68]
BALB/c MHOM/IL/80/Friedlin ++ ND ND [67]
BALB/c MHOM/IL/(0/Friedlin +++ +/- +++ [69]
BALB/c MHOM/IR/-/173 ++ + + [70]
C57BL/6 MHOM/IL/80/Friedlin + ++ - [71]
C57BL/6 MHOM/IR/-/173 + ++ - [70]
107 BALB/c MHOM/IL/80/Friedlin ++++ +/- ++ [68]
BALB/c MHOM/IL/80/Friedlin +++ +/- ++ [67]
BALB/c MHOM/IR/-/173 ++ ND ND [70]
C57BL/6 MHOM/IR/-/173 + ND ND [70]
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characterized by the absence of lesions and the increase
of the parasite load. During the second phase, lesions
develop (footpad swelling) associated with immune cell
infiltration at the site of infection. Concomitantly, Th1
cells expand in the draining lymph nodes, ultimately
leading to parasite burden reduction and lesion healing.
Inoculation site
In experimental studies on CL, only the intradermal
route of inoculation is used, but at different sites: hind
footpad, ear pinna and tail base (Table 6). Depending on
the inoculation site, the clinical signs (lesion size and
immune response) clearly differ. Moreover, the cytokine
production profile does not always explain the disease
severity [73, 74].
In BALB/c mice, severe, non-healing lesions were ob-
served whatever the inoculation site [73, 74], and they
were associated with a classical Th2 immune response
[73, 74].
In SWR mice, inoculation at the base of the tail led to
the development of large non-healing lesions, whereas
self-healing lesions were observed following inoculation
in the hind footpad [73]. Unexpectedly, inoculation at
the tail base tail induced a Th1 immune response, which
is normally associated with self-healing lesions.
This dichotomy was also observed in resistant mice, such
as the C57BL/6J strain. After inoculation in the ear pinna,
the classical Th1 response was associated with the develop-
ment of small, self-healing lesions. Conversely, parasite in-
oculation at the tail base, induced a Th2 response that was
unexpectedly associated with lesion healing [74].
C3H/HeN and DBA/2 mice were resistant to CL
caused by ear pinna inoculation of Leishmania parasites,
but presented intermediate disease (C3H) or were fully
susceptible (DBA/2) when inoculated at the tail base
[74]. Again, no clear correlation was found between the
type of immune response and the cutaneous lesion se-
verity. For instance, C3H/HeN mice were fully resistant
to L. major infection through the ear pinna, but no Th1
response could be detected.
CBA/H mice were resistant to L. major infection
through any inoculation site, with an immune response
similar to controls [74].
Thus, besides the parasite dose and mouse genetic
background, the infection site also affects CL severity.
Influence of phlebotome saliva
Several studies assessed the role of the vector saliva in
CL development.
When L. major parasites were inoculated with saliva from
Lutzomyia longipalpis, the size of cutaneous lesions in CBA
and BALB/c mice was five to ten times bigger and con-
tained at least 5000 times more parasites than in controls
(no saliva) [75]. Moreover, when inoculated at low doses,
parasites survived only when co-injected with saliva [75].
This disease exacerbation effect was observed in other
mouse strains (susceptible, intermediate susceptible or re-
sistant) and was more pronounced in resistant CBA and
C57BL/6 mice [76]. Salivary gland extracts from L.
longipalpis exacerbated CL following infection by L.
major [78] or by L. braziliensis [57, 78]. It has been
demonstrated that maxadilan, a salivary vasodilator, is
Table 6 Influence of the inoculation site on cutaneous lesion size and immune response
Inoculation site Mouse strain Lesion size Th1 response Th2 response Reference
Hind footpad BALB/c +++ + +++ [73]
SWR + +++ +
C57BL/6J +/- ND ND
Ear pinna BALB/c +++ - ++ [74]
C57BL/6J + ++ -
DBA/2 +/- - +/-
C3H/HeN - +/- +
CBA/H - - +/-
Tail base BALB/c ++ - ++ [74]
C57BL/6J +/- + +
DBA/2 ++ - -
C3H/HeN + ++ -
CBA/H +/- - -
BALB/c ++ + +++ [73]
C57BL/6J - ND ND
SWR ++ + +/-
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responsible for the disease-exacerbation effect of saliva
from L. longipalpis [79].
Phlebotomus papatasi saliva also can increase lesion
size, but with a less pronounced effect than saliva from
L. longipalpis [76]. Moreover, inoculation of parasites
with P. papatasi saliva in resistant CBA mice led not
only to bigger lesion size, but also to higher parasite burden
in lesions that was associated with a modulation of the im-
mune response (decrease of Th1 factors and increase of
Th2-associated IL4 production) [80]. When mimicking nat-
ural infection by injection of low dose of parasites in the
ear dermis, co-inoculation of P. papatasi saliva promoted
lesion development (earlier and higher parasitemia) in
BALB/c and also in C57BL/6 mice [81]. This was associated
with Th2 immune response induction and IL4 production.
Additional experimental parameters
To our knowledge, only one study in BALB/c mice de-
scribed the influence of L. major infectious stage on (i)
lesion development and ulceration and (ii) on the type
of immune response [82]. Specifically, after inoculation
of high doses (106) of metacyclic promastigotes (infective
stage) in the ear dermis (pinna), lesions were detectable
1 week after infection and became ulcerate after 4 weeks.
Following inoculation of high doses (106) of log-phase
parasites (division stage), detectable lesions and ulcera-
tions were observed after three and 10 weeks, respect-
ively. Moreover, inoculation of log-phase parasites led to
better activation of lymph node CD4+ T cells (IFNγ pro-
duction) than inoculation of metacyclic promastigotes,
at least during the early stages of infection (16 h and
3 days post-inoculation).
In addition, the presence of apoptotic promastigotes in
the infectious inoculum is important for the parasite
intracellular survival and, thus, for disease development
in vivo [83]. Although this parameter must be further in-
vestigated, it has to be taken into account when design-
ing in vivo experiments.
In summary, when studying CL, the route of infection,
the infectious parasite stage, the inoculated dose or the
adjuvant, the mouse resistance or susceptibility to infec-
tion are all essential parameters to be taken into account
because they can substantially influence the issue of
in vivo experiments.
Conclusions
In conclusions, this review underlines that many param-
eters have to be taken into account for the in vivo study
of L. donovani complex or L. major infection in mouse
models of VL and CL.
From the host genetic point of view, it seems more
complex controlling CL than VL. Indeed, several loci are
involved in CL control and each locus regulates specific
features of the disease (i.e., IgG secretion, parasite load,
lesion size). Although the use of an animal model limits
the influence of the environment, the choice of the
mouse genetic background is crucial. For instance, a
sensitive mouse strain is more suitable for comparing
the infection outcome of various Leishmania strains and
for rapid assessment of the parasite virulence and/or
pathogenicity.
Concerning the immune response (resistance/suscepti-
bility phenotype), in VL, mice are clearly classified ac-
cording to their capacity to sustain parasite persistence
in organs. In CL, parasites could persist at the infection
site in resistant mice, thus giving a lifelong immunity to
reinfection.
For both CL and VL, the parasite genotype clearly
affects the infection outcome; however, it is difficult to
correlate the results obtained in animal models with
clinical observations in human patients.
The parasite dose and the route of inoculation need
also to be carefully considered.
Inoculation through the intradermal route must be
performed with high dose of parasite inoculum to give
effective viscera infection during VL, whereas low doses
can be used for CL with parasites dissemination to vis-
ceral organs in susceptible mice. In the case of L. infan-
tum infection, different immune responses are observed
in function of the inoculation route and this can strongly
influence the outcome. Thus, to study the chronic phase
of the infection, an inoculation route that promotes the
parasite long-term establishment (intravenous route)
must be preferred. Conversely, when studying the acute
phase, the inoculated dose (high doses leading to more
intense immune response) is the crucial point. For L.
major, the key parameters seem to be the dose and its
association with sandfly saliva. Low doses are recom-
mended for immunization studies, but not for strain
virulence assessment. Indeed, at low doses, lesion devel-
opment is controlled in susceptible mice, except when
saliva is simultaneously injected. Effective lesion devel-
opment requires inoculation of high doses, leading to
the development of ulcers the severity of which is directly
correlated with the strain virulence.
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